# **NeuroPal**: 一个结合睡眠时间治疗、认知行为重构和适应性植物化学干预的临床导向多模态LLM心理健康助手

发布时间：2025年05月10日

`LLM应用` `心理健康` `智能助手`

> NeuroPal: A Clinically-Informed Multimodal LLM Assistant for Mental Health Combining Sleep Chronotherapy, Cognitive Behavioral Reframing, and Adaptive Phytochemical Intervention

# 摘要

> 鉴于时间限制，中国心理健康专业人士难以提供长时间的谈话疗法，导致心理障碍患者（包括睡眠紊乱、饮食失调、认知偏差和肠胃功能紊乱等症状）面临治疗缺口。为解决这一问题并实现大规模干预，我们开发了NeuroPal——一个基于大型语言模型（LLM）的智能助手，提供可扩展、循证的干预方案，包含三个临床验证模块：(1) 睡眠节律规划器，生成个性化生物钟调整方案；(2) 认知-行为重构引擎，基于CBT和人本主义原理，帮助改善负面思维模式；(3) 生化调节顾问，提供草药疗法配方，平衡睡眠-代谢-肠道轴功能。与北京协和医院和中南大学湘雅医院合作，我们对513名情绪/焦虑障碍患者开展随机对照试验（RCT），结果显示主要指标显著改善（p < .01）。具体表现为：匹兹堡睡眠质量指数（PSQI）下降37.2%，积极情感表达增加28.6%（LIWC分析），患者消化舒适度提升23.4%。此外，NeuroPal的依从率达到89.1%，显著高于传统人工引导治疗的72.3%。研究结果表明，LLM驱动的多模态干预方案不仅有效，还能突破时间限制，保持治疗效果。未来，我们将进一步探索长期疗效追踪及FDA/CFDA认证路径。

> Due to time constraints, mental health professionals in China are unable to offer patients prolonged talk therapy, leaving a gap in care for patients with psychological disorders, including aberrant sleep and eating patterns, maladaptive explanatory styles, and gastrointestinal dysfunction. To bridge this gap in care and address these problems in a large-scale manner, we built NeuroPal, a large language model (LLM)-assistant that provides scalable, evidence-based interventions with three clinically validated modules: (1) a sleep chronotherapy planner to output personalized circadian rhythm correction protocols, (2) a cognitive-behavioral reframing engine grounded in CBT and humanistic principles to shift negative attributional biases, and (3) a biochemical regulation advisor to output phytotherapy formulations to regulate sleep-metabolism-gut-axis imbalances. In collaboration with Peking Union Medical College Hospital and Xiangya Hospital Central South University, we ran an RCT protocol with 513 participants with mood/anxiety disorders and showed statistically significant improvements towards primary endpoints (> p<.01). Experiment shows 37.2% drop in the Pittsburgh Sleep Quality Index (PSQI), 28.6% rise in positive affective word usages (LIWC analysis), and 23.4% improvement in patient-reported digestive comfort. The assistant also reached 89.1% adherence rates, significantly higher than the human-guided therapy intervention (72.3%) in matched controls. Our results indicate that an LLM-driven multimodal intervention is able to successfully bridge time-constrained clinical practice while preserving therapeutic effectiveness. For next steps, we plan to explore longitudinal outcome tracking and FDA/CFDA certification routes.

[Arxiv](https://arxiv.org/abs/2505.06640)